



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/615,041

07/08/2003

Hiroyuki Otaki

CU-5982

3932

26530 7590 03/04/2009
LADAS & PARRY LLP
224 SOUTH MICHIGAN AVENUE
SUITE 1600
CHICAGO, IL 60604

EXAMINER

ANGEBRANNDT, MARTIN J

ART UNIT

PAPER NUMBER

1795

MAIL DATE

DELIVERY MODE

03/04/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/615,041	Applicant(s) OTAKI ET AL.	
	Examiner Martin J. Angebrannt	Art Unit 1795	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 18 December 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,5-8,10-13,15-19,21-24 and 30-38 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,5-8,10-13,15-19,21-24,30-38 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1795

1. The application has been revived in response to the petition from the applicant filed 10/09/2008. This petition was granted 6/26/2008. Rejections of the previous office action, not repeated below are withdrawn based upon the arguments and the amendment to the claims. The certified translation of the priority documents have been received and also serve to obviate some rejections. The proper terminal disclaimer filed 12/18/08 obviates the ODP rejection made.

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claims 1,5-8,10-13,15-19,21-24 and 30-38 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Coumalin” should read - - coumarin - - and “ketocoumalin” should read - - ketocoumarin - - .

In claims 1, 16,17,18,23,24,30,32,35,37 and 38, “fluorine-contained” should read - - fluorine containing- - .

In claim 30, “fluorine skeleton-contained” should read - - fluorene skeleton containing - - .

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 1795

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. Claims 32-34 and 37-38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sugawara et al. JP 05-273899, in view of Toba et al. JP 06-175554 .

Sugawara et al. JP 05-273899 see example 2, where the monomer having the formula 20 is used to improve the qualities of a volume hologram which was formed from a composition comprising PVCz, tribromophenol methacrylate, a benzophenone and a coumarin sensitizer. [0048]. Useful binders are disclosed including polyvinyl acetate and acrylic resins and copolymers of acrylic acid. [0008-0009]. Useful photoinitiators include benzoin alkyl ethers, benzophenone, iodonium salts and the like [0024,0041]. The use of sensitizers, including merocyanine (meroshinin) dyes to increase the sensitivity of the composition is disclosed. [0025].

Toba et al. JP 06-175554 teaches the use of merocyanine sensitizers in holographic recording compositions including the dye of formula k [0057]. These are used to sensitize iodonium salt initiated free radical polymerization (abstract and throughout). The use of fluorinated acrylates which have high refractive indices is disclosed. [0024]. The inclusion of polymers is disclosed.

It would have been obvious to modify the composition of example 2 of Sugawara et al. JP 05-273899 by using other photoinitiators and sensitizers disclosed, such as iodonium salts and merocyanine dyes taught by Toba et al. JP 06-175554 based upon the direction in Sugawara et al. JP 05-273899 at [0024-0025]. Further it would have been obvious to use other binders of

Art Unit: 1795

copolymers or copolymer blends such as polyvinyl acetate-acrylic acid based upon the direction at [0008-0009] in Sugawara et al. JP 05-273899. The applicant points out that the composition in the examples includes a holographic image prior to holographic recording. The argument fails to appreciate that the addition of a further monomer, initiator, and sensitizer as discussed at [0024-0025,0041] allows further recording of holographic images (multiplexing). The reacted monomer and any initially included binders are effectively binders at this juncture. The Toda reference(s) teach the recited sensitizing dye.

7. Claims 18,19 and 21-24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sugawara et al. JP 05-273899, in view of Morii et al. 378.

Morii et al. '378 teaches volume holographic material with particles in them to improve breaking during foil/heat transfer these include various fine particles. (6/6-14, 40/65-41-64). The refractive index of the particles is described as almost identical to the photosensitive material/composition, which clearly indicates as difference. The use of fluorinated carboxylic acids [fluorinated (meth)acrylates] (12/54,13/57-14/5). Useful binders disclosed include vinylacetate, vinylalcohol, PVC, and others (15/37-56). The use of various sensitizing dyes including cyanine, merocyanine, coumarin, ketocoumarin dyes is disclosed (15/29-35).

It would have been obvious to modify the composition of example 2 of Sugawara et al. JP 05-273899 by adding fine particles of silica or the like as taught by Morii et al. '378 to allow its use in holographic transfer foils. Further it would have been obvious to use other binders of copolymers or copolymer blends such as polyvinyl acetate-acrylic acid based upon the direction at [0008-0009] in Sugawara et al. JP 05-273899 of the binders taught by Morii et al. '378.

Art Unit: 1795

8. Claims 32-38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sugawara et al. JP 05-273899, in view of Toba et al. JP 06-175554, further in view of Ito et al. JP-08-016077.

Ito et al. JP 08-016077 teaches a mixture of cationically curable and free radically curable monomer, onium salts and a sensitizing dye useful for holographic recording which evidences improved chemical, heat and weatherability resistance. The cationically curable material can include a fluorene moiety as illustrated in formulae 1-3 [0028-0030]. The sensitizing dye can be various dyes including merocyanine dyes [0020,0035-0041]. The useful onium salts are disclosed including iodonium and sulfonium salts [0034]

In addition to the basis above, it would have been obvious to one skilled in the art to modify the media rendered obvious by the combination of Sugawara et al. JP 05-273899 and Toba et al. JP 06-175554 by adding a cationically curable monomer/oligomer containing fluorene and initiator for this as taught by Ito et al. JP 08-016077 to improve the heat, weather and chemical resistance of the resulting hologram.

9. Claims 1,5,7,8,10-12,15-17 and 30-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kashiwagi et al. JP 03-123715, in view of Toda et al. JP 06-130879.

Kashiwagi et al. JP 03-123715 teaches the composition of example2, in table 1, where a epoxy monomers DPEP, PRGE and HDEP (structures shown on page 7) are included with triphenylsulfonium hexafluorophosphate (identified on page, lower left column). The addition of resinous binders is disclosed. These include epoxy resins, acrylate resins, epoxy(meth)acrylate resins, urethane acrylates, polybutadiene acrylate and modified products (page 2, lower left

Art Unit: 1795

column, first full paragraph) . The use of various UV light sources including mercury, carbon, xenon or fluorescent lamps is disclosed. (page 6/lower right column, first full paragraph)

Toda et al. JP 06-130879 teaches the use of merocyanines to sensitize sulfonium salts in holographic recording compositions including the dyes of formula K [0041]. These are used to sensitize sulfonium salt initiated free radical polymerization (abstract and throughout). The use of fluorinated acrylates which have high refractive indices is disclosed. [0024]. The inclusion of polymers is disclosed. The use of these in recording with lasers or UV light sources is disclosed [0062].

It would have been obvious to add a resinous binder to the composition of example 2 of Kashiwagi et al. JP 03-123715 based upon the direction on page 2 and to add sensitizing agents known to be useful with sulfonium salts, such as the merocyanine dye (k) taught by Toda et al. JP 06-130879 to increase the sensitivity of the composition, noting that the sensitized composition are evidenced to be useful with the same UV light sources taught Kashiwagi et al. JP 03-123715.

The examiner agrees that the claims are not anticipated, but the claims embrace the media irrespective of the intended use. The claims are not limited to the use of this composition in recording a hologram, but embrace the composition irrespective of use. The benefit of sensitization taught by Toda et al. JP 06-130879 clearly extends to the UV sources taught by Kashiwagi et al. JP 03-123715 based upon the disclosure of these UV light sources in both references.

10. Claims 1,5-8,10-12,15-17 and 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kawabata et al.. '340 and Kashiwagi et al. JP 03-123715.

Art Unit: 1795

Kawabata et al. '340 in examples 16-18, a mixture of cationically curable materials, free radical curable materials (bis(4-acryloxydiethoxyphenyl)methane), a radically polymerization initiator, a sensitizing dye (dye 1) and a triphenylsulfonium hexafluorophosphate as the cationic polymerization initiators (table 4, col 11) which was applied to a glass plate and overcoated with a polyethylene film, exposed to the interference light and then postcured with a flood exposure from a mercury lamp (7/55-8/40). The use of various onium salts is disclosed. (6/8-18). The use of fluorinated epoxies, glycidyl ether and oxiranes are disclosed (3/8-4/3). The use of various acrylates is disclosed (4/4-46). Useful free radical initiators are disclosed (4/47-5/47).

It would have been obvious to one skilled in the art to modify the examples of Kawabata et al. '340 by using fluorinated epoxies, such as those taught by Kashiwagi et al. JP 03-123715 with a reasonable expectation of success based upon the direction to fluorinated epoxies by Kawabata et al.. '340.

The applicant argues that no fluorinated monomers are taught in Ohkuma et al. and the examiner points to "1,4-bis(2,3-epoxypropoxyperfluoroisopropyl)cyclohexane, 1,6-dimethylolperfluorohexane diglycidyl ether, 4,4'-bis(2,3-epoxypropoxyperfluoroisopropyl)diphenyl ether in column 3, so there is direction to fluorinated monomer. The examiner also points out that some of the examples use halogenated monomers, (bromine) which would also have a high refractive index.

11. Claims 1,5-8,10-13,15-17 and 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kawabata et al.. '340 and Kashiwagi et al. JP 03-123715, further in view of Morii et al. 378.

Art Unit: 1795

It would have been obvious to modify the composition rendered obvious by the combination of Kawabata et al., '340 and Kashiwagi et al. JP 03-123715 by adding fine particles of silica or the like as taught by Morii et al. '378 to allow its use in holographic transfer foils.

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Martin J. Angebranndt whose telephone number is 571-272-1378. The examiner can normally be reached on Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mark Huff can be reached on 571-272-1385. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Martin J Angebranndt/
Primary Examiner, Art Unit 1795

Martin J Angebranndt
Primary Examiner
Art Unit 1795

3/1/2009